Imiquimod in the Treatment of Cutaneous Warts: An Evidence-Based Review

@article{Ahn2014ImiquimodIT,
  title={Imiquimod in the Treatment of Cutaneous Warts: An Evidence-Based Review},
  author={Christine S. Ahn and William Wei-ting Huang},
  journal={American Journal of Clinical Dermatology},
  year={2014},
  volume={15},
  pages={387-399}
}
  • C. Ahn, W. Huang
  • Published 2014
  • Medicine
  • American Journal of Clinical Dermatology
IntroductionCutaneous warts are highly prevalent lesions caused by the infection of keratinocytes by different types of human papillomaviruses. Although cutaneous warts are capable of resolving spontaneously, these infections can persist for long periods of time by evading the host immune system, and, as a result, many patients choose to seek treatment. Imiquimod is an immune response modifier that is approved as a topical cream for the treatment of anogenital warts by the US Food and Drug… Expand
Efficacy of intralesional immunotherapy for the treatment of warts: A review of the literature
TLDR
Intralesional vaccine injection represents a safe, effective, and tolerable treatment for warts, including recalcitrant and anogenital warts. Expand
Therapeutic management of cutaneous and genital warts
  • H. Ockenfels
  • Medicine
  • Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • 2016
TLDR
The objective of the present review article is to analyze the study data currently available, taking into consideration both subtypes and locations – factors exceedingly crucial in clinical practice. Expand
Evolving role of immunotherapy in the treatment of refractory warts
TLDR
The mechanism of action of these immunotherapeutic agents, along with their dosage, mode of administration, duration of use, expected outcomes and comparative efficacy, evidence for their use, and expected side effects, if any, are reviewed. Expand
Intra-anal use of imiquimod: what is the clinical evidence?
TLDR
The present clinical evidence suggests that imiquimod may be proposed as effective, safe, and relatively well tolerated treatment in the treatment of human papillomavirus-related anal lesions. Expand
Imiquimod in dermatology: an overview
TLDR
Existing evidence on the mechanism of action of topical imiquimod, its FDA‐approved indications, off‐label uses, and side effects are described. Expand
Evaluation of therapeutic effectiveness of vitamin D3 injections in common warts in a tertiary care centre
TLDR
Intralesional Vit D3 injections may be a treatment option for warts, which has a good cosmetical acceptance and simple, well tolerated easily administrated in outpatient clinic rather than conventional treatment. Expand
Treatment of warts and molluscum: what does the evidence show?
TLDR
Strong, high-quality evidence for treatments used very frequently for warts or molluscum is still lacking, but recent publications have helped to strengthen or weaken belief in commonly used therapies and to add weight to the immunological approach to management. Expand
Photothermal therapy enhanced the effectiveness of imiquimod against refractory cutaneous warts through boosting immune responses.
TLDR
It is demonstrated that ISPI can be used as an effective and safe treatment modality for refractory cutaneous warts and there was no recurrence or worsening in both groups during the 12-month follow-up. Expand
Use of imiquimod in the treatment of chronic periungual warts
Warts are the most frequent periungual tumors presented in dermatological consultations. They are caused by several types of human papillomavirus (HPV), and some of these lesions evolve to aExpand
Wart Immunotherapies: A Short Review
TLDR
Immunotherapies for recalcitrant warts present as a cost-effective, efficient therapy option for patients and have the added benefit of affecting warts at locations distant to the target location by inducing a systemic Tcell mediated response in the body. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 50 REFERENCES
Treatment of Cutaneous Warts
TLDR
From pooled evidence-based medicine data, it is possible to conclude that significantly higher remission rates may be expected only with cryotherapy and salicylic acid used in combination. Expand
Efficacy of Imiquimod 5% Cream in the Treatment of Recalcitrant Warts in Children
TLDR
It is demonstrated that the topical application of imiquimod 5% cream is an effective treatment for long‐lasting cutaneous warts in children. Expand
Plantar warts treated with an immune response modifier: a report of two cases
TLDR
Total clearance of the warts was observed in both cases after treatment with imiquimod 5% cream over a period of 12 weeks, and no evidence of local skin reactions was observed during the treatment period. Expand
Successful treatment of facial plane warts with imiquimod
TLDR
The treatment of plane warts with imiquimod that was associated with a striking inflammatory component was reported, and after 2 weeks the warts had resolved completely. Expand
Topical 5% Imiquimod Long-Term Treatment of Cutaneous Warts Resistant to Standard Therapy Modalities
TLDR
The data demonstrate that the long-term topical application of imiquimod 5% cream is an effective treatment for otherwise therapy-resistant cutaneous warts without causing any meaningful side-effects. Expand
Successful treatment of multiple filiform facial warts with imiquimod 5% cream in a patient infected by human immunodeficiency virus
TLDR
It is felt that imiquimod could be used in HIV‐infected patients with multiple facial warts in whom conventional therapies are ineffective or produce significant side‐effects. Expand
5% Topical Imiquimod Tolerance in Transplant Recipients
TLDR
Imiquimod 5% cream is a promising, well-tolerated therapy for warts, AK and BP in transplant recipients in transplant patients. Expand
A review of imiquimod 5% cream for the treatment of various dermatological conditions
TLDR
Current literature suggests that IRMs, including imiquimod, activate the immune response via specific cell-surface receptors called Toll-like receptors (TLRs), which results in the activation of an antigen-specific adaptive immune response. Expand
Topical treatment of common warts in an HIV‐positive patient with imiquimod 5% cream
TLDR
Following 5 months of treatment with imiquimod, an immune response modifier, as a 5% cream, complete clearance of all warts was achieved in a 41‐year‐old HIV‐positive man with multiple common warts located on his hands and feet. Expand
Treatment of extramammary Paget disease of the vulva with imiquimod: a retrospective, multicenter study by the German Colposcopy Network.
TLDR
When associated cancers and invasive growth are excluded, imiquimod appears to be a useful treatment option for recurrent EMPD and may avoid extensive mutilating surgical treatment. Expand
...
1
2
3
4
5
...